Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients
Open Access
- 22 January 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 25 (1), 1-3
- https://doi.org/10.1186/s13054-021-03470-3
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trialThe Lancet Respiratory Medicine, 2020
- Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the LiteratureVascular Health and Risk Management, 2020
- Atrial Fibrillation in Patients with Septic Shock: A One-Year Observational Pilot StudyTurkish Journal of Anaesthesiology and Reanimation, 2019
- Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational studyIntensive Care Medicine, 2012
- Incidence and prognostic impact of new-onset atrial fibrillation in patients with septic shock: a prospective observational studyCritical Care, 2010
- In rabbits, landiolol, a new ultra-short-acting β-blocker, exerts a more potent negative chronotropic effect and less effect on blood pressure than esmololCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2001